TITLE

Resting heart rate and cardiovascular events: risk factor or risk marker?

AUTHOR(S)
Ker, James
PUB. DATE
August 2012
SOURCE
South African Pharmaceutical Journal;2012, Vol. 79 Issue 4, p45
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the association of resting heart rate with all-cause mortality in addition to cardiovascular mortality. According to the Framingham Heart study, high resting heart rate is associated with an increase in cardiovascular mortality in people and also found in people with hypertension, acute myocardial infarction and heart failure and ventricular dysfunction. It also presents information on the heart rate-lowering drug, ivabradine.
ACCESSION #
76307681

 

Related Articles

  • Lack of B vitamins may clog arteries.  // Environmental Nutrition;Mar1995, Vol. 18 Issue 3, p1 

    Reports on the findings of the Framingham Heart Study on high blood levels of the amino acid homocysteine as an important indicator of risk for heart attack. Increase in risk in lower blood levels of B vitamin folate and vitamin B6.

  • Blood pressure warning...  // FDA Consumer;Jan/Feb2000, Vol. 34 Issue 1, p5 

    Reveals the findings of a Framingham Heart Study showing the dangers of not treating people with elevated systolic high blood pressure. Move of the United States (US) National Institutes of Health about the findings; How systolic blood pressure is produced; People in the US with high blood...

  • Heart rate: surrogate or target in the management of heart failure? Böhm, Michael; Reil, Jan-Christian // Heart;Jan2013, Vol. 99 Issue 2, p72 

    The author reflects on the role of heart rate in the management of heart failures. It focuses on high resting heart rates, which may result in cardiovascular diseases like atherosclerosis, myocardial infarction and heart failure. High heart rates are a reflection of neurohormonal activation and...

  • BEAUTIFUL: no go for go slow with ivabradine?  // Heart;Jan2009, Vol. 95 Issue 2, p171 

    The article discusses the effectiveness of ivabradine, a heart-rate-lowering agent, in preventing cardiovascular death and mortality in patients with coronary heart disease and impaired systolic function. A BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with...

  • Heart Rate Variability in Acute Myocardial Infarction. Garan, Hasan // Cardiology;2009, Vol. 114 Issue 4, p273 

    The author reflects on the retrospective analysis conducted by E. Karp and colleagues to determine the heart rate variability (HRV) of patients undergoing recovery from acute myocardial infarction (AMI). He notes that the authors use rhythm strip to ease the risk factor obtained through...

  • Effect of Chronic Heart Rate Reduction by If Current Inhibitor Ivabradine on Left Ventricular Remodeling and Systolic Performance in Middle-Aged Rats With Postmyocardial Infarction Heart Failure. Dedkov, Eduard I.; Bogatyryov, Yevgen; McCooey, Daniela Scaldaferri; Christensen, Lance P.; Weiss, Robert M.; Tomanek, Robert J. // Journal of Cardiovascular Pharmacology & Therapeutics;May2015, Vol. 20 Issue 3, p299 

    The article focuses on a study which determines whether long-term inhibitor ivabradine (IVA) therapy can sustainably maintain the beneficial impact of pure heart rate reduction on left ventricular (LV) remodeling and systolic performance in middle-aged rats with heart failure (HF) due to a large...

  • FAST FACTS.  // MLO: Medical Laboratory Observer;Feb2020, Vol. 52 Issue 2, p6 

    Statistics are presented related to cardiovascular disease which include number of fatal heart attacks, percentage of the American population affected by cardiovascular disease and number of people who die in the U.S. every year from heart disease.

  • P666 Heart rate control protects against ischemia-reperfusion injury. Delgado Betancourt, V; Covihnes, A; Mesirca, P; Bidaud, I; Nargeot, J; Piot, C; Striessnig, J; Mangoni, ME; Barrere-Lemaire, S // Cardiovascular Research;Jul2014, Vol. 103 Issue suppl_1, pS121 

    Acute myocardial infarction (AMI) is the major cause of cardiovascular mortality worldwide. Early reperfusion is the only treatment recommended to reduce infarct size (IS). However, reperfusion presents also deleterious effects such as ischemia-reperfusion (IR) injury due to irreversible...

  • Cardioprotection by Ivabradine Through Heart Rate Reduction and Beyond. Heusch, Gerd; Skyschally, Andreas; Schulz, Rainer // Journal of Cardiovascular Pharmacology & Therapeutics;Sep2011, Vol. 16 Issue 3/4, p281 

    The present review summarizes the experimental and clinical evidence for the anti-ischemic action of the selective bradycardic agent ivabradine. Improvements in myocardial blood flow and contractile function during experimental myocardial ischemia and the clinical anti-anginal effect are largely...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics